News

Govt Bars Medical Reps from Hospitals to Curb Pharma Influence

In a decisive move to curb pharmaceutical lobbying within the public healthcare system, the Centre has directed all central government hospitals to prohibit the entry of medical representatives, effectively ending in-person interactions between pharma sales teams and doctors.

• By Newsdesk
• New Delhi
• Jun 03, 2025

News

In a decisive move to curb pharmaceutical lobbying within the public healthcare system, the Centre has directed all central government hospitals to prohibit the entry of medical representatives, effectively ending in-person interactions between pharma sales teams and doctors.

The directive, issued by the Directorate General of Health Services (DGHS) on May 28, instructs hospital authorities to strictly enforce the ban and ensure medical representatives no longer access hospital premises to promote drugs or treatments. Instead, pharmaceutical companies must rely on digital platforms, such as email or online briefings, to share updates about new medicines or clinical developments.

This measure is part of the government’s broader attempt to dismantle the longstanding and controversial nexus between pharmaceutical companies and medical practitioners—a relationship often criticised for promoting biased prescription practices through the use of incentives, gifts, or free drug samples.

The DGHS has emphasized that this step is not only aimed at limiting undue influence but also at reducing disruptions to hospital functioning caused by unscheduled meetings between doctors and sales representatives.

Pharma Code Tightened to Rein in Unethical Marketing

The new directive builds on last year’s implementation of the Uniform Code for Pharmaceuticals Marketing Practices (UCPMP), a voluntary framework designed to instill ethical standards in the industry. The code bars pharmaceutical firms from offering any form of inducement—be it gifts, paid trips, or financial grants—to healthcare professionals or their family members. It also prohibits the distribution of free drug samples to individuals not authorized to prescribe medicines.

Legal and Regulatory Push for Generics

This crackdown comes amid growing judicial and regulatory pressure to promote the use of generic medicines in India. In a landmark observation in May, the Supreme Court noted that doctors across the country should be required to prescribe generic drugs over branded ones, highlighting the need for affordable and equitable access to essential medicines.

Generic drugs, which mirror branded medications in composition and efficacy, are seen as a vital solution to rising healthcare costs in India.

In 2023, the National Medical Commission (NMC) attempted to formalize this shift by mandating doctors to prescribe only generics, warning that non-compliance could result in penalties, including licence suspension. However, the move faced fierce resistance from the Indian Medical Association (IMA), which questioned the logic of licensing branded drugs if their prescription was to be discouraged.

Following strong backlash from the medical community, the NMC was forced to defer the implementation of these guidelines.

A Step Toward Transparent Healthcare

The Centre’s latest decision signals a clear policy shift toward transparency and ethical governance in India’s healthcare system. While the long-term impact of this directive remains to be seen, it marks a strong message: public health must be free from commercial interests.